BioSpace News Archive

Waters Corporation will webcast its Q1 2021 financial results conference call live on Wednesday, May 5th, 2021 at 8:00 a.m. eastern time.

Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection in appropriate patients across all approved US indications.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 per share pursuant to the underwriter’s over-allotment option granted in connection with the Company’s recent public offering,

Tevogen Bio, a pioneering immunotherapy company, announces that Dr. Neal Flomenberg, MD, Professor and Chairman of the Department of Medical Oncology at Thomas Jefferson University, will present preclinical data of TVGN-489, Tevogen’s investigational allogeneic cytotoxic T cell therapy for COVID-19 at the 2021 Annual Meeting of the American Association of Immunologists (AAI)

FARE, the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research, announced the addition of Michael Frazier as Executive Vice President and Chief Business Officer.

Livanta LLC is pleased to announce its recent award of a national claim review task order under the Centers for Medicare & Medicaid Services’ Beneficiary and Family Centered Care - Quality Improvement Organization program.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fiscal year 2021 financial results will be released after the market closes on Wednesday, May 12, 2021.

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be reporting financial results for the first quarter 2021 before market open on Tuesday, May 11, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the presentation of promising data from the Company’s growing bispecific platform at the American Association of Cancer Research (AACR) Annual Meeting 2021 being held April 10 th – 15 th .